ライフサイエンスコーパス: endoglycosidase

1 ns are first deglycosylated with a wild-type endoglycosidase.

2 Heparanase is a heparan sulfate degrading endoglycosidase.

3 in SDS-PAGE before and after treatment with endoglycosidase.

4 e supernatant, indicating the presence of an endoglycosidase activity.

5 lglucosamine (GlcNAc) of IgG, using a mutant endoglycosidase (also called endoglycosynthase) that lac

6 ompounds were identified by a combination of endoglycosidase and exoglycosidase digestions, anion-exc

7 ere determined by treating each protein with endoglycosidases and then subjecting it to sodium dodecy

8 Protein endoglycosidases are useful for biocatalytic alteration

9 The Endo-F3 mutants represent the first endoglycosidase-based glycosynthases capable of transfer

10 o mutants described here represent the first endoglycosidase-based glycosynthases enabling a highly e

11 In this article, we report studies of two endoglycosidase-based glycosynthases, EndoM-N175A and En

12 from Streptococcus pneumoniae (Endo-D) is an endoglycosidase capable of hydrolyzing the Fc N-glycan o

13 fringens ATCC10543 were contaminated with an endoglycosidase capable of releasing the disaccharide Gl

14 Glycosylation remodeling using the endoglycosidase-catalyzed deglycosylation and transglyco

15 We describe herein the optimization of an endoglycosidase-catalyzed glycosylation of the best-sell

16 ha-mannosidase inhibitor kifunensine, and an endoglycosidase-catalyzed glycosylation of the deglycosy

17 Endoglycosidase-catalyzed in vitro glycoengineering tech

18 in vitro enzymatic glycosylation, using the endoglycosidase-catalyzed transglycosylation as the key

19 e containing two GlcNAc residues and a novel endoglycosidase-catalyzed transglycosylation that simult

20 the GlcNAc-primer in the IgG1-Fc through an endoglycosidase-catalyzed transglycosylation, using suga

21 is of novel N-glycan clusters using a tandem endoglycosidase-catalyzed transglycosylation.

22 Heparanase, an endoglycosidase, colocalized with perlecan in the baseme

23 eral hours to overnight) and relatively high endoglycosidase concentration (from 1:250 to 1:500 enzym

24 d here provides a framework from which novel endoglycosidases could be engineered for additional clin

25 utant TREM2 becomes sensitive to cleavage by endoglycosidase D under conditions that inhibit recyclin

26 Hyaluronidase (HAase), an endoglycosidase, degrades HA into small angiogenic fragm

27 Heparanase is an endoglycosidase degrading heparan sulfate, of the baseme

28 sylation, in contrast to previously reported endoglycosidases derived from Endo-S, Endo-M, Endo-D, an

29 Surface biotinylation and endoglycosidase digestion experiments showed that TcGP63

30 Endoglycosidase digestion followed by SDS/PAGE, lectin a

31 ither tunicamycin treatment of the cells nor endoglycosidase digestion of calreticulin resulted in an

32 We identified an 88-kDa secreted protein, endoglycosidase (Endo) E, which is most likely responsib

33 nes , EndoS, is complementary to other known endoglycosidases (EndoA, EndoH) used for current protein

34 analysis using a combination of IdeS and the endoglycosidases EndoS and EndoS2 to comprehensively map

35 ost common human pathogens, secretes a large endoglycosidase, EndoS, which removes carbohydrates in a

36 icken erythroid AE1 anion exchangers receive endoglycosidase F (endo F)-sensitive sugar modifications

37 CD38 HL-60 ADPR-cyclase to inactivation by N-endoglycosidase F and to thermal inactivation at 45 degr

38 ectants after removal of sugar residues with endoglycosidase F or following tunicamycin treatment to

39 und to be resistant to digestion with either endoglycosidase F or H but sensitive to peptide N-glycos

40 with high concentrations of N-glycosidase F, endoglycosidase F, endoglycosidase H, and endo-beta-gala

41 retic mobility was altered by treatment with endoglycosidase F.

42 Da which are converted to 155 and 115 kDa by endoglycosidase F.

43 We modified the N-glycan of SZ21 by endoglycosidase F.

44 Deglycosylation of PHF tangles by endoglycosidase F/N-glycosidase F converts them into bun

45 protein) which was sensitive to tunicamycin, endoglycosidase F/N-glycosidase, and endoglycosidase H b

46 cted by treatment of the cells with trypsin, endoglycosidase F/peptide N-glycosidase F, Vibrio choler

47 o CNS-type NMDAR1 after deglycosylation with endoglycosidase F/peptide-N-glycosidase F.

48 Treatment of platelet membranes with endoglycosidase-F causes the P2X1 receptor band to migra

49 ceptor (obtained by enzymatic treatment with Endoglycosidase-F/N-glycosidase-F).

50 NPR-ECD deglycosylated with endoglycosidase F2 and endoglycosidase H retained ANP-bi

51 sidase assisted analysis using sialidase and endoglycosidase F2/F3, respectively, to improve resoluti

52 labeled with 2-aminobenzamide, digested with Endoglycosidases F2 and H followed by normal phase HPLC

53 Digestion of monoclonal antibodies with Endoglycosidases F2 and H, which cleave the glycosidic b

54 derived from Elizabethkingia meningoseptica endoglycosidase F3 (Endo-F3) of the GH18 family, which a

55 ed by site-directed mutagenesis of EndoS (an endoglycosidase from Streptococcus pyogenes ) and were f

56 Here we reveal that a bacterial endoglycosidase from Streptococcus pyogenes , EndoS, is

57 a systematic site-directed mutagenesis of an endoglycosidase from Streptococcus pyogenes of serotype

58 poptotic factors (i.e. Smac/DIABLO, AIF, and endoglycosidase G).

59 Treatment with PNGase F, but not Endoglycosidase H (Endo H) (specific for high-mannose N-

60 was determined by proteinase K digestion and endoglycosidase H (Endo H) cleavage.

61 lex (pgCIII) was sensitive to treatment with endoglycosidase H (endo H), while the mature gCIII compl

62 ted with the presence of a limited amount of endoglycosidase H (Endo H)-resistant HLA-F.

63 pike protein (S) was newly synthesized as an endoglycosidase H (endo H)-sensitive glycoprotein (gp170

64 n-19 is not utilized; Asn-39 is linked to an endoglycosidase H (Endo H)-sensitive oligosaccharide, an

65 alnexin), yet surface TPO molecules remained endoglycosidase H (endo H)-sensitive.

66 dases peptide-N-glycosidase F (PNGase F) and endoglycosidase H (Endo H).

67 s, the N-linked sugars remained sensitive to Endoglycosidase H (Endo H).

68 ficantly reduced in cd81(-/-) B cells and is endoglycosidase H (endo-H) resistant.

69 Endoglycosidase H (endo-H) treatment of particles demons

70 However, endoglycosidase H (endoH) digestion of the viral envelop

71 onnatural sugars at N-glycan core positions, endoglycosidase H (endoH)-digested peptides from a purif

72 nt molecular weights and remained completely endoglycosidase H (endoH)-sensitive, suggesting incomple

73 val, (ii) all detectable processed mMDC15 is endoglycosidase H -resistant, and (iii) a recombinant so

74 Digestion of gp120 with endoglycosidase H abrogates the binding of SP-A, indicat

75 Pulse-chase and endoglycosidase H analysis demonstrate that the iHeps re

76 Cell surface biotinylation and endoglycosidase H analysis revealed a 128-kDa precursor

77 Endoglycosidase H analysis revealed that the modified En

78 cognized by this antiserum were sensitive to endoglycosidase H and associated with calnexin, indicati

79 igomers; however, they remained sensitive to endoglycosidase H and did not undergo endoproteolytic cl

80 were established by pulse-chase analysis and endoglycosidase H and glycopeptidase F digestions.

81 Digestion with N-glycosidase F, endoglycosidase H and lectin blotting did not reveal any

82 Endoglycosidase H and peptide N-glycosidase treatment an

83 nous parasite glycoproteins using sequential endoglycosidase H and peptide:N-glycosidase-F digestions

84 e and mature GC-C glycoforms on the basis of endoglycosidase H and PNGase sensitivities.

85 US7, US9, and US10 remained sensitive to endoglycosidase H and were exclusively or largely presen

86 CPD increases to 180 kDa and is resistant to endoglycosidase H as a result of carbohydrate maturation

87 PP I proenzyme with both N-glycosidase F and endoglycosidase H as well as treatment of the cells with

88 amycin, endoglycosidase F/N-glycosidase, and endoglycosidase H but not to O-glycosidase.

89 , and both mature proteins were resistant to endoglycosidase H but sensitive to glycopeptidase F.

90 Treatment with endoglycosidase H caused an increase in electrophoretic

91 Endoglycosidase H cleaved the 45-kDa band to approximate

92 Effects of tunicamycin and endoglycosidase H confirmed that these novel isoforms re

93 y limited trypsin digestion and treated with endoglycosidase H deglycosidase to reduce heterogeneity

94 ecular mass in SDS-PAGE and was resistant to endoglycosidase H deglycosidase.

95 Peptide N-glycosidase F and endoglycosidase H deglycosylate hENT1 to 37 kDa and hENT

96 but in alpha1(A322D)beta2gamma2S receptors, endoglycosidase H deglycosylated 91 +/- 4% of alpha1(A32

97 In alpha1beta2gamma2S receptors, endoglycosidase H deglycosylated only 26 +/- 5% of alpha

98 However, cell surface biotinylation and endoglycosidase H digestion assays appear to under-repre

99 Endoglycosidase H digestion assays indicated that SALM1D

100 n sensitivity to both mannan competition and endoglycosidase H digestion compared to that of the 124m

101 Pulse-chase analysis and endoglycosidase H digestion of surface-biotinylated MMP-

102 Endoglycosidase H digestion of the mutated TfRs indicate

103 Endoglycosidase H digestion showed that a significant fr

104 on of flow cytometry, patch clamp recording, endoglycosidase H digestion, brefeldin A treatment, and

105 Endoglycosidase H digestion, immunocytochemistry, and su

106 elet Mpl, PV platelet Mpl was susceptible to endoglycosidase H digestion, indicating defective Mpl pr

107 gglutinin at a stage preceding resistance to endoglycosidase H digestion, thus impairing hemagglutini

108 Experiments employing endoglycosidase H indicated that the early slow processi

109 The acquisition of resistance to endoglycosidase H indicated trafficking of S to the medi

110 Yet, endoglycosidase H insensitivity indicates an aberrant ol

111 By monitoring acquisition of endoglycosidase H resistance after metabolic labeling, w

112 tution mutant S proteins displayed levels of endoglycosidase H resistance and cell surface expression

113 se media reversibly inhibited development of endoglycosidase H resistance and mannose-binding activit

114 ldin A required more than 120 min to acquire endoglycosidase H resistance and maximal binding activit

115 slational processing of these two mutants to endoglycosidase H resistance and very low cell surface e

116 e cell surface have the potential to acquire endoglycosidase H resistance as a consequence of Golgi-b

117 he ER is confirmed by the failure to acquire endoglycosidase H resistance at 37 degrees C and cannot

118 d with a 45-min half-time for development of endoglycosidase H resistance.

119 D deglycosylated with endoglycosidase F2 and endoglycosidase H retained ANP-binding activity and show

120 leavage site mutant I was N glycosylated and endoglycosidase H sensitive, indicating that ER transloc

121 cular chaperones BiP and GRP94, and remained endoglycosidase H sensitive, suggesting retention in the

122 emonstrated that the M(r) 85,000 species was endoglycosidase H sensitive, suggesting targeting of the

123 Endoglycosidase H sensitivity assays showed that N-linke

124 munofluorescence microscopy and constitutive endoglycosidase H sensitivity in metabolically labeled c

125 between the two cell lines as determined by endoglycosidase H sensitivity of newly sensitized P-glyc

126 al immature glycosylation, manifest by their endoglycosidase H sensitivity.

127 dopsin as judged by mobility on SDS/PAGE and endoglycosidase H sensitivity.

128 We used the glycosidase endoglycosidase H to determine that this difference in m

129 tor N-butyldeoxynojirimycin and treated with endoglycosidase H to remove all but the terminal N-acety

130 We have used endoglycosidase H to remove the Asn-linked glycans from

131 d material to dense lysosomes was delayed in endoglycosidase H treated cells, but the rate of degrada

132 Pulse-chase experiments in combination with endoglycosidase H treatment determined that the mutant m

133 Endoglycosidase H treatment of microsomes containing nas

134 d be inhibited by d-mannose and abolished by endoglycosidase H treatment of THP, suggesting that the

135 Endoglycosidase H treatment of ts045VSVG-GFP confirmed t

136 Endoglycosidase H treatment resulted in the removal of o

137 In addition to transcription/translation, endoglycosidase H treatment was used to verify glycosyla

138 class I molecules exhibiting sensitivity to endoglycosidase H treatment.

139 and only the 93-kDa wt C2 were sensitive to endoglycosidase H, a marker for transport from the endop

140 tions of N-glycosidase F, endoglycosidase F, endoglycosidase H, and endo-beta-galactosidase.

141 ith neuraminidase, resistance to cleavage by endoglycosidase H, and GalNAc-independent labeling with

142 mutant receptor to peptide-N-glycanase F and endoglycosidase H, and insensitivity to sialidase indica

143 138 and Asn-175 were completely sensitive to endoglycosidase H, and they were phosphorylated.

144 porate the J chain and resist degradation by endoglycosidase H, arguing for IgM passage through the G

145 from mPmel17 not only in its sensitivity to endoglycosidase H, but also in the content of core 1 O-g

146 Peptide N-glycosidase F, but not endoglycosidase H, digestion converted all beta1 to an a

147 treatment of target cells with tunicamycin, endoglycosidase H, or protease (pronase).

148 ome processed fertilin alpha is sensitive to endoglycosidase H, suggesting cleavage occurs prior to t

149 lted in some enzyme that lost sensitivity to endoglycosidase H, suggesting that the first disulfide b

150 TR-infected cells, gO remained sensitive to endoglycosidase H, suggesting that the protein was not e

151 toreceptors, P/rds was robustly sensitive to endoglycosidase H, which is consistent with its bypassin

152 In this study, we describe an endoglycosidase H-deglycosylated form of TPP1 containing

153 The structures, determined at 1.85 A for the endoglycosidase H-deglycosylated protease domain produce

154 n the Cbeta domain, was thrombin-cleaved and endoglycosidase H-digested, and the two derivatives were

155 ecules are delayed in their maturation to an endoglycosidase H-resistant form after biosynthetic labe

156 ed ADAM3 exhibited an increased amount of an endoglycosidase H-resistant form that may be related to

157 nverted to the Golgi-processed and therefore endoglycosidase H-resistant form, and the endoglycosidas

158 he Ostalpha subunit to a mature glycosylated endoglycosidase H-resistant form, suggesting that co-exp

159 ed medium, these chains were converted to an endoglycosidase H-resistant form.

160 SP-B and SP-BDeltaC remained in cells in an endoglycosidase H-resistant form.

161 dified by N-linked glycosylation to a mature endoglycosidase H-resistant form.

162 t product being a relatively unstable 24-kDa endoglycosidase H-resistant glycoprotein.

163 pancies of numerous N-glycosylation sites by endoglycosidase H-resistant N-glycans originating from M

164 rporated into POMC predominantly on N-linked endoglycosidase H-resistant oligosaccharides.

165 alpha subunit, but not non-cleaved alpha, is endoglycosidase H-resistant.

166 cosylation sites and unknown numbers of both endoglycosidase H-sensitive and -resistant oligosacchari

167 Endoglycosidase H-sensitive class I molecules were detec

168 l cytoplasmic domain show that they exit the endoglycosidase H-sensitive compartment at a slower rate

169 x glycosylation of wild-type AQP2 but mainly endoglycosidase H-sensitive core glycosylation of AQP2-T

170 re endoglycosidase H-resistant form, and the endoglycosidase H-sensitive ER form has a half-life of 2

171 retained in the endoplasmic reticulum in an endoglycosidase H-sensitive form associated with the mol

172 rbohydrate chains of SCAP were mostly in the endoglycosidase H-sensitive form when cells were grown i

173 s of S and MHVR via coimmunoprecipitation of endoglycosidase H-sensitive forms of the two proteins.

174 within the endoplasmic reticulum as immature endoglycosidase H-sensitive forms.

175 ells, CPD is initially produced as a 170-kDa endoglycosidase H-sensitive glycoprotein.

176 crystals were composed of correctly folded, endoglycosidase H-sensitive IgG.

177 sed surface IgM coupled with accumulation of endoglycosidase H-sensitive IgM intracellularly, resembl

178 NAc2-PP-dolichol transferred by TbSTT3A, and endoglycosidase H-sensitive N-glycans originating from M

179 ocol; describes the presence of full-length, endoglycosidase H-sensitive NSP4 in plasma membrane cave

180 The enzyme contains endoglycosidase H-sensitive oligosaccharides that contai

181 d-type gE were synthesized as N-glycosylated endoglycosidase H-sensitive precursors with approximate

182 This Man(6)GlcNAc(2) is the endoglycosidase H-sensitive product of the Alg3p step.

183 peared mostly as a 70-kDa core-glycosylated, endoglycosidase H-sensitive, immature form bound to the

184 ome cells, it is sensitive to digestion with endoglycosidase H.

185 as assessed by acquisition of resistance to endoglycosidase H.

186 ecular weight form and gained sensitivity to endoglycosidase H.

187 mmature form was sensitive to digestion with endoglycosidase H.

188 se and O-glycanase but not to treatment with endoglycosidase H.

189 s a 45-kDa glycoprotein that is sensitive to endoglycosidase-H and is reduced to 37-kDa after N-glyca

190 Endoglycosidase-H digests and colocalization with endopl

191 ling studies demonstrate that acquisition of endoglycosidase-H resistance of CD1d is observed in the

192 and gamma(c) chains associated with p12I are endoglycosidase-H sensitive, suggesting that their inter

193 is expressed on the cell surface as a 48-kDa endoglycosidase-H-resistant glycoprotein.

194 es, but the currently limited selectivity of endoglycosidases has prevented effective manipulation of

195 The endoglycosidase heparanase specifically cleaves the hepa

196 ell-associated molecules leads to sequential endoglycosidase (heparanase) fragmentation of the chains

197 dels to investigate the contributions of the endoglycosidase HYAL1 and the exoglycosidase beta-hexosa

198 Introduction of both the engineered mAb and endoglycosidase in serum leads to a dramatic increase in

199 Inhibition of heparanase (an HS endoglycosidase) in in vitro cultured HFs has been shown

200 cellular production of functional vIL-6, but endoglycosidase-mediated removal of N-linked glycans fro

201 eless, neither Endo-A nor the Mucor hiemalis endoglycosidase mutants (EndoM-N175A and EndoM-N175Q) we

202 to short glycosaminoglycans by the action of endoglycosidases or heparanases.

203 Application of an endoglycosidase, peptide N-glycosidase F (PNGaseF), dire

204 ed peptides, and the glycans released by the endoglycosidase PNGase F.

205 Endoglycosidase S (EndoS) is a glycoside-hydrolase secre

206 -chain deglycosylation with bacteria-derived endoglycosidase S (EndoS).

207 Specifically, we show that (i) EndoS (endoglycosidase S) cleaves only complex-type glycans of

208 st in two distinct glycoforms with different endoglycosidase sensitivities.

209 dentified by molecular weight determination, endoglycosidase sensitivity, and microsequencing analysi

210 Endoglycosidase studies demonstrated that both products

211 The actions and specificities of endoglycosidases such as a peptide-N-glycosidase F (PNGa

212 Heparanase is an endoglycosidase that cleaves heparan sulfate side chains

213 Heparanase (the only known mammalian endoglycosidase that cleaves heparan sulfate) is essenti

214 Gs can be cleaved by HPR1 (heparanase-1), an endoglycosidase that is overexpressed in many types of m

215 Hyaluronidase is a hyaluronic acid-degrading endoglycosidase that is present in many toxins and the l

216 Heparanase-1 (HPR1) is an endoglycosidase that specifically degrades the heparan s

217 Heparanase is an endoglycosidase that specifically degrades the unbranche

218 based proteomics strategy that uses specific endoglycosidases to introduce mass signatures that disti

219 using mass spectrometry in conjunction with endoglycosidase treatment and tryptic digestion.

220 Endoglycosidase treatment demonstrated presence of an in

221 Endoglycosidase treatment of the full-length ANP recepto

222 Tunicamycin and endoglycosidase treatments determined the extent of rNKp